News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 639 results
March 2017
-
Media ReleaseNew analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
-
Media ReleaseNovartis' Cosentyx® shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause- 94% of patients regained their PASI 75 response and the majority re-achieved their PASI 90 or 100 response after 16 weeks of Cosentyx 300 mg retreatment(1)- Patients may need to pause treatment due…
-
Media ReleaseNovartis' Cosentyx® shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
December 2016
-
Media ReleaseAlcon receives US FDA approval for AcrySof® IQ ReSTOR® +3.0D Multifocal Toric intraocular lens for cataract patients- New intraocular lens (IOL) combines two technologies that correct for presbyopia and corneal astigmatism simultaneously- This IOL is a new option for patients who desire good near, intermediate and…
-
Media ReleaseAlcon receives US FDA approval for AcrySof® IQ ReSTOR® +3.0D Multifocal Toric intraocular lens for cataract patients
-
Media ReleaseNovartis out-licenses three COPD products in the USSunovion assumes US commercialization rights for Utibron™ Neohaler®, Seebri™ Neohaler® and Arcapta® NeohalerNovartis will continue to manufacture these important medicines for SunovionIn line with…
-
Media ReleaseNovartis out-licenses three COPD products in the US
-
Media ReleaseNovartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL- 82% (41 of 50) of patients achieved complete remission or complete remission with incomplete blood count recovery in interim analysis of Novartis study (ELIANA)- ELIANA, the first global CAR T cell…
-
Media ReleaseNovartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL
November 2016
-
Media ReleaseNew analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deathsEntresto reduced the risk of first and subsequent events of heart failure hospitalizations and cardiovascular deaths following heart failure hospitalization by 20%-24% compared to enalapril (1)These…
-
Media ReleaseNew analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths
-
Media ReleaseAlcon introduces new AIR OPTIX® plus HydraGlyde monthly replacement contact lenses at the American Academy of Optometry annual meetingThis is the latest addition to the Alcon AIR OPTIX® portfolio of monthly replacement contact lenses which merges two unique technologiesSmartShield® Technology provides excellent deposit resistance…
Pagination
- ‹ Previous page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- …
- 54
- › Next page